Orquest plans launch in 2000 for Healos:
This article was originally published in Clinica
Executive Summary
Orquest, a Mountain View, California-based orthobiologics company, plans to launch its Healos bone graft substitute for spinal fusion in Europe next year. The company has a strategic alliance with Sulzer Spine-Tech for the CE-marked product, which is being evaluated for use with the BAK line of interbody fusion cages. The company is also developing an integrated growth differentiation factor-5, Healos/GDF-5, as a replacement for autograft. Another product, Ossigel, is designed to accelerate fracture healing by stimulating cell division and blood vessel formation within the fracture site. Ossigel, which is an injectable formulation of basic fibroblast growth factor and hyaluronic acid gel, is currently in clinical trials in the US and Europe.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.